FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BERENSON RONALD J						2. Issuer Name <b>and</b> Ticker or Trading Symbol XCYTE THERAPIES INC [ XCYT ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
DEIGE										X Direct			10% Ov						
(Last)	(Fir	est) (	Middle)		3. Date of Earliest Transaction (Month/Day/Year)									X Office below	(give title		Other (s below)	pecify	
C/O XCYTE THERAPIES							03/19/2004								President & C.E.O.				
1124 COLUMBIA STREET, SUITE 130																			
1124 COLUMDIA STREET, SUITE 130							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable				
(Street)						4. II Amendment, Date of Original Filed (Month/Ddy/Year)								e)					
SEATTLE WA 98104														X Form	filed by One	ne Reporting Perso		ı	
															Form filed by More than One Reporting				
(City)	(Sta	ate) (	Zip)											Perso	11				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						ar) E	2A. Deemed Execution Date, If any Month/Day/Year)		Code (	Transaction Code (Instr.		es Acquire Of (D) (Inst		Benefic Owned	es ially Following	Form (D) o	: Direct   I r Indirect   I str. 4)   (	7. Nature of ndirect Beneficial Dwnership	
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)		[	Instr. 4)	
Common Stock 03/19/					9/2004	2004			С		10,526	6 A	\$5.22	25 403	03,667(1)		D		
Common Stock													38	,358			By Γrust <sup>(2)</sup>		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
														1					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, Transa Code (I					6. Date E Expiratio (Month/D	n Dat	of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Series A Convertible Preferred	(3)	03/19/2004			С			10,526	(4)		03/19/2004	Common Stock	10,526	\$5.225	0		D		

## **Explanation of Responses:**

- 1. 30,207 of these shares are subject to a repurchase right in favor of the issuer, which will lapse on September 1, 2005.
- 2. These shares are held by the Irrevocable Intervivos Trust Agreement of Ronald J. Berenson and Cheryl L. Berenson.
- 3. 1-for-1
- 4. Immediately

/s/ Joanna Lin Black, as

Attorney-in-Fact for Ronald J.

**Berenson** 

\*\* Signature of Reporting Person Date

03/23/2004

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.